Encision INC

Encision Inc. announced its decision to voluntarily deregister its common stock and suspend its reporting obligations with the SEC, citing high compliance costs.

Encision, Inc. announces the resignation of CEO and Director Gregory Trudel due to strategic disagreements, appointing long-time board member Robert Fries as Interim CEO.

Encision, Inc. announced the resignation of director Patrick Pace, effective October 30, 2025, citing no disputes with the company.

Encision Inc. announced the completion of a $500,000 private placement and the results of its Annual Meeting of Stockholders, including the election of four directors and approval of executive compensation.

Encision Inc. held its annual meeting on August 15, 2024, electing five directors and ratifying its independent accounting firm.

Encision Inc. announced a net income of $22 thousand for the first quarter of fiscal year 2025, a significant improvement compared to a net loss of $140 thousand in the same quarter of the previous year.

Encision Inc. reported a significant increase in net loss and a decrease in product revenue for the quarter ended September 30, 2025, despite securing $500,000 through a private placement to bolster working capital.

Encision Inc. reported a net loss of $41,133 for the quarter ended June 30, 2025, primarily driven by a 6% decrease in product revenue.

Encision Inc. reports a decreased net loss for Q3 2025, driven by improved gross margins, despite a slight decrease in product revenue.

Encision Inc. reports a net loss for the quarter ended September 30, 2024, despite increased service revenue and efforts to expand market awareness of its AEM technology.

Encision Inc. reported a net income of $22,041 for the quarter ended June 30, 2024, a significant improvement from a net loss in the same period last year, despite a slight decrease in product revenue.

Encision Inc. reported a decrease in product revenue and an increased net loss for the third quarter of fiscal year 2024, alongside ongoing efforts to improve internal controls and expand market reach.

Encision Inc., a medical device company specializing in patient safety technology for minimally invasive surgery, reported a significant reduction in net loss and an increase in gross profit for fiscal year 2025, driven by higher service revenue and improved product margins, despite a slight decrease in overall product revenue.

Encision Inc. reported a decrease in revenue for fiscal year 2024, while highlighting its commitment to expanding its patented Active Electrode Monitoring (AEM) technology.

Envision Inc. CEO Robert Fries has acquired a significant number of company shares through a Rule 10b5-1(c) plan, indicating a strong belief in the company's future prospects.

ENCISION INC's CEO and Director, Gregory J. Trudel, was granted options to purchase 10,000 shares of common stock at an exercise price of $0.25, vesting over approximately five years.

Encision Inc. Director Vern D. Kornelsen was granted 10,000 stock options with an exercise price of $0.25, vesting over time.

ENCISION Inc.'s VP of Marketing, Brian J Jackman, was granted options to purchase 10,000 shares of common stock at an exercise price of $0.25.

CMED Partners LLLP, a 10% owner and director, significantly increased its stake in Encision Inc. by purchasing 2 million shares in a private placement.

ENCISION INC CEO Gregory J. Trudel purchased 1,000,000 shares of common stock at $0.10 per share in a private placement.

Encision Inc. has filed its definitive proxy statement outlining proposals for its upcoming Annual Meeting, including the election of four directors, ratification of auditors, and advisory votes on executive compensation.

Encision Inc. will hold its Annual Meeting of Shareholders on August 15, 2024, to elect directors and ratify the appointment of independent public accountants.

Encision Inc.'s Vice President of Finance, Brandon J Shepard, has increased his beneficial ownership in the company to 6.0% through a recent private placement and option exercises.

Encision Inc.'s CEO, Gregory J. Trudel, increased his beneficial ownership to 8.7% by purchasing 1,000,000 shares in a private placement for $100,000.

Encision Inc. Director Robert H. Fries increased his beneficial ownership to 8.2% by purchasing 750,000 shares in a private placement for $75,000.

Thalassa Holdings, Ltd. and its Executive Chairman, Duncan Soukup, have jointly disclosed a beneficial ownership of 5.21% in Encision Inc., holding 619,272 shares for investment purposes.